ONCODNA
OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.
The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank with the significant support of SFPI-FPIM. Historical shareholders together with CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW have also participated. This represents another landmark achievement after the €8 million Series A fundraising closed in September 2016.
OncoDNA is now maximizing the fast and proper rollout of its oncology clinical decision support software OncoKDM® with the objective of becoming the European leader in oncogenomic data interpretation and reporting to further support molecular laboratories, healthcare professionals and the pharma industry in their daily research and clinical practice.
Jean-Pol Detiffe, Founder & Chief Executive Officer at OncoDNA : “We are delighted to have successfully raised sufficient new capital from such quality investors who will enable us to grow and increase our support to oncologists and cancer patients with our data driven solutions. OncoDNA is already positioned as the European champion for cancer precision medicine as we built a worldwide network of more than several thousand oncologists. Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors.”
Guy Geldhof, Partner at Vesalius Biocapital III S.C.A. SICAR said: “We are excited about co-leading the Series B investment in OncoDNA. It is thrilling to work with a team that has both world class experience in genomic molecular profiling and a strong desire to serve patients by offering best-in-class support to oncology professionals. We are confident OncoDNA will accelerate the development and commercialization of its valuable new solutions, especially through closer collaborations with the biopharma industry, with the final objective of contributing to better healthcare .”
Robert Schier, Partner at Swisscanto (CH) Private Equity Switzerland Growth I KmGK added: “OncoDNA has grown significantly over the past years and are continuing to add the necessary clinical expertise and know-how to act upon its mission. Its disruptive vision and highly integrated market approach make it to be the perfect candidate to rapidly become the European leader in oncology big data. We are delighted to partner with OncoDNA as we firmly believe the company contributes to both a more sustainable healthcare system and improved patient health outcomes.”
“Considering our important investment in OncoDNA, alongside players like Vesalius Biocapital III and Swisscanto, we are convinced that the company has all the necessary means at a key moment of its development to successfully carry out appropriate projects to assist and support oncologists in prescribing the most optimal therapeutic treatments to patients. We are happy to count on the support of our colleagues from SRIW and Sambrinvest as historical stakeholders” concluded François Fontaine, at SFPI-FPIM.
OncoDNA
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities who would like to reach the same level of expertise, we provide them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, employs 50 employees in 4 countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200214005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clearwater Analytics Embeds AI into Beacon Risk Platform to Accelerate Model Validation and Exposure Analysis27.1.2026 10:00:00 CET | Press release
Production-grade AI transforms quantitative workflows—from scenario analysis to tail risk modeling—inside investment risk operations engine Clearwater Analytics(NYSE: CWAN), the most comprehensive technology platform for investment management, today announced breakthrough embedded agentic AI capabilities within Beacon by CWAN, its enterprise risk and quantitative analytics platform, enabling risk teams to accelerate model validation, exposure analysis, and decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126906084/en/ As regulatory scrutiny intensifies and portfolio complexity reaches unprecedented levels, traditional risk platforms are failing institutional investors when they need answers most. Built specifically for quantitative developers and risk professionals managing complex institutional portfolios, CWAN’s embedded AI operates within Beacon’s calculation engine itself, training the agents our client
Seasoned European Software Executive David Coste to Join Battery Ventures27.1.2026 09:00:00 CET | Press release
Coste, a longtime leader at pan-European ERP provider Forterro, will be a Battery executive-in-residence Battery Ventures, the global, technology-focused investment firm, announced it has hired former Forterro executive David Coste as an executive-in-residence based in its London office, effective next month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127122321/en/ David Coste, a former Forterro executive who begins a new executive-in-residence role with global investment firm Battery Ventures in London in February. At Battery, Coste will work closely with Battery Partner Zak Ewen and General Partner Morad Elhafed, among others, to help source and evaluate business-technology investments throughout Europe. Battery first opened its London office in 2016 and, since 2005, has completed more than 150 transactions across 13 countries including the U.K., Germany, France, the Netherlands, Belgium, Switzerland, Sweden and Nor
Castles Technology Partners With Loomis Pay to Power European Expansion With Next-Generation Android Devices27.1.2026 08:00:00 CET | Press release
Cutting-edge Android payment and Point-of-Sales (POS) technology set to transform the European payments and POS landscape Castles Technology, a global leader in Android payment acceptance devices, has been selected by Loomis Pay, the POS and digital payment division of Loomis, to support its European expansion. Through this collaboration, Loomis Pay will strengthen its capacity to deliver flexible and secure POS and payment solutions tailored to merchant preferences. As well as empowering merchants and their customers to transact the way they prefer, cash, card and digital. Following an extensive market review, Loomis Pay chose Castles Technology for its leadership in Android-based payment solutions, recognized for versatility, reliability, and innovation across its latest Android devices. Loomis Pay will deploy their POS and payment services on the portable S1F4 Pro, the PINPAD S1P2 and the unattended S1U2M4, as well its CasHUB TMS and Marketplace. Castles Technology and Loomis Pay ha
EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures27.1.2026 07:00:00 CET | Press release
EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/ The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively
Ohana Development and Manchester City F.C. Sign Agreement to Launch Multi-Billion-Dirham Project in Abu Dhabi27.1.2026 07:00:00 CET | Press release
The 1.67 million square metre development is the world’s first Manchester City branded residential destination Ohana Development, a leading UAE real estate developer renowned for its luxury properties, has signed an agreement with Manchester City F.C. to launch ‘Manchester City Yas Residences by Ohana’, a first-of-its-kind branded residential community, set along Abu Dhabi’s Yas Canal waterfront. The partnership reflects a shared commitment to excellence, innovation and long-term value creation, reinforcing Abu Dhabi’s position as a global destination for world-class developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126122700/en/ Standing: HE Khaldoon Al Mubarak, Chairman of Manchester City Football Club. Left to right: Husein Salem, CEO of Ohana Development and Ferran Soriano, CEO of City Football Group. (Photo: AETOSWire). Spanning 1.67 million square metres, ‘Manchester City Yas Residences by Ohana’ draws on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom